Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma 17Leukemia, Myeloid, Acute 16Breast Neoplasms 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Multiple Myeloma 12Lymphoma, Large B-Cell, Diffuse 12Lymphoma, Non-Hodgkin 11Carcinoma, Non-Small-Cell Lung 11Lymphoma, Mantle-Cell 10Leukemia 10Lymphoma, Follicular 9Hodgkin Disease 9Myelodysplastic Syndromes 8Recurrence 7Neuroblastoma 7Neoplasm Metastasis 7Leukemia, Lymphocytic, Chronic, B-Cell 7Brain Neoplasms 7Neoplasms, Plasma Cell 6Lymphoma, B-Cell, Marginal Zone 6Lung Neoplasms 6Glioblastoma 6Prostatic Neoplasms 5Pancreatic Neoplasms 5Lymphoma, T-Cell, Cutaneous 5Lymphoma, T-Cell 5Lymphoma, Large-Cell, Anaplastic 5Lymphoma, B-Cell 5Immunoblastic Lymphadenopathy 5Burkitt Lymphoma 5

Interventions

mirdametinib 1Vorinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Primary Malignant Peripheral Nerve Sheath Tumors × Vorinostat × Clear all
NCT06693284 2026-05-29

A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]

University of Minnesota

Phase EARLY_PHASE1 Recruiting
8 enrolled

Primary Malignant Peripheral Nerve Sheath Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡